Neurosense Therapeutics Ltd (NRSN) — Defensive Interval Ratio

Latest as of June 2025: 140 days

Neurosense Therapeutics Ltd (NRSN) has a Defensive Interval Ratio of 140 days as of June 2025. Defensive assets of $847.00K (cash $-, short-term investments $-, receivables $847.00K) cover 140 days of daily cash needs of $6.04K/day. Check NRSN tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

140 days
Days of operational coverage

Defensive Assets

$847.00K
Cash + ST Investments + Receivables

Daily Cash Need

$6.04K
Current Liabilities ÷ 365

Current Liabilities

$2.20 Million
USD

Neurosense Therapeutics Ltd Defensive Interval Ratio (2019–2024)

This chart shows how Neurosense Therapeutics Ltd's Defensive Interval Ratio has evolved across 6 annual periods from 2019 to 2024. As of June 2025, the ratio stands at 140 days, meaning defensive assets of $847.00K can fund 140 days of operations without new revenue. Also explore Neurosense Therapeutics Ltd net asset momentum to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Neurosense Therapeutics Ltd (2019–2024)

The table below presents the year-by-year Defensive Interval Ratio for Neurosense Therapeutics Ltd from 2019 to 2024, covering 6 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see Neurosense Therapeutics Ltd (NRSN) total market value.

Year DIR (days) Defensive Assets (USD) Daily Cash Need Cash ST Investments Change (days)
2024 30 days $164.00K $5.46K/day $- $- ▲ +13 days
2023 18 days $166.00K $9.48K/day $- $0.00 ▼ -760 days
2022 778 days $3.68 Million $4.73K/day $- $3.55 Million ▲ +669 days
2021 109 days $178.00K $1.64K/day $- $0.00 ▲ +18 days
2020 91 days $30.00K $328.77/day $- $- ▼ -86 days
2019 178 days $18.00K $101.37/day $- $-
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)